Iga Jancewicz

6PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 05, 2024
Correction to: New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.

Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska

|Jan 27, 2024
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.

Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska

|Aug 27, 2021
PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells.

Iga Jancewicz, Joanna Szarkowska, Ryszard Konopinski

|May 18, 2021
Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1,6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report.

Michal Szymanski, Natalia Rusetska, Iga Jancewicz

|Apr 07, 2020
Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines.

Monika Swiatek, Iga Jancewicz, Jakkapong Kluebsoongnoen

|Feb 20, 2020
SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer.

Malgorzata Stachowiak, Michal Szymanski, Anna Ornoch

Pageof 1

Frequent Collaborators

4 joint publications

Tomasz J Sarnowski

4 joint publications

Elzbieta Sarnowska

3 joint publications

Janusz A Siedlecki

2 joint publications

Magdalena Winiarska